Although the synthetic lethal relationship between Pol γ and MLH1 leads to the selective killing of MLH1 deficient cancer cells by showing minimal cytotoxicity to MLH1 proficient cells, transporting CR to mitochondria with nanocarrier systems will likely improve its stability and therapeutic effect, reduce off-target effects and decrease its toxicity. Here, MLH1 is linked to cancer.